The major news this week was the Hinge Health IPO, the first for digital health in two years–but the downside was that it was at a lower valuation. Denouements abounded with most 23andMe genetic ...

Leading our news with a short, heartwarming story. The White House’s proposed discretionary budget for FY 2026 calls for an increase of nearly $2.2 billion in funding for the EHR program as a “top ...

More on this in Strata-gee 15 May. More good news– Editor Ted Green is recuperating and back at his desk, if only part-time. He has been invaluable for his inside looks at Masimo’s endless drama over ...

Hinge Health now public. Today (22 May) Hinge Health debuts as HNGE on the NYSE, the first big IPO for healthcare tech in two years. Last night, the virtual MSK/physical therapy provider raised $437.3 ...

Most of 23andMe bought for a lot more than one could have thought–and why? Yesterday, the board of 23andMe confirmed that they have a court-approved definitive agreement for the sale of their core ...

The Synchron Stentrode device is still in clinical trials and has been in development since 2012. Synchron achieved the first BCI in 2019. In March, they and NVIDIA announced Chiral, a foundation ...

This was drastic. This morning (13 May), UnitedHealth Group announced that CEO Andrew Witty is stepping down immediately “for personal reasons” which are not specified. Replacing him is former ...

One after another surprise this week. UnitedHealth Group changed out CEOs suddenly. The new one is a surprising ‘blast from the profitable past’ but that didn’t stop Mr. Market from taking the stock ...

Omada Health’s IPO filing kicked off the week’s news. The chronic condition care management company is the second with a major IPO this year, stirring a dormant healthcare market. There aren’t a lot ...